SCHEMBL4389889

SCHEMBL4389889

CCCCOCCCNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.50
RECQL P46063 1/20 0.50
ALDH1A1 P00352 4/20 0.43
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
ABL1 P00519 1/20 0.39
BCR P11274 1/20 0.39
KDM4E B2RXH2 1/20 0.39
HDAC3 O15379 4/20 0.39
HDAC1 Q13547 4/20 0.39
HDAC2 Q92769 1/20 0.39
CYP1A2 P05177 1/20 0.39
POLB P06746 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HDAC6 Q9UBN7 3/20 0.38
PREP P48147 1/20 0.38
FAP Q12884 1/20 0.38
SCN10A Q9Y5Y9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5669715 0.95 HDAC3 (0.43) TSHRRECQLALDH1A1MEN1KMT2A
SCHEMBL5667723 0.92 ABL1 (0.44) ALDH1A1MEN1KMT2AABL1BCR
SCHEMBL5667982 0.86 KDM4E (0.47) TSHRRECQLMEN1KMT2AKDM4E
SCHEMBL5669968 0.85 CYP1A2 (0.41) ALDH1A1MEN1KMT2AHDAC3HDAC1
SCHEMBL5667971 0.85 HDAC3 (0.41) ALDH1A1MEN1KMT2AHDAC3HDAC1
SCHEMBL4388201 0.85 CYP1A2 (0.39) ALDH1A1MEN1KMT2AHDAC3HDAC1
SCHEMBL2172869 0.85 CYP1A2 (0.43) ALDH1A1MEN1KMT2AKDM4ECYP1A2
SCHEMBL4389229 0.85 CYP1A2 (0.40) ALDH1A1MEN1KMT2AHDAC3HDAC1
SCHEMBL5670705 0.83 ALDH1A1 (0.40) ALDH1A1MEN1KMT2AHDAC3HDAC1
SCHEMBL4392420 0.82 CYP1A2 (0.52) ALDH1A1MEN1KMT2ACYP1A2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2009-07-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE ALK, BCL3, MCL1 TSHR 1413/4885RECQL 3277/4885ALDH1A1 1466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.